Protocol Index	

If this file opens in Compatibility Mode using Microsoft Word, convert to the latest document format to avoid potential formatting issues.	

OP RESEARCH PRO00038509 C2321014 ARM A EFSTATHIOU	

Types:      Research Oncology Treatment
Synonyms:  

Cycle 1	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 25	Interval: --	Occurrences: --	Comments:	Randomization
		  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --				Day 15	Perform every 1 day x1		Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --				Day 22	Perform every 1 day x1		Nursing Orders
  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
					
Cycle 2	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --				Day 15	Perform every 1 day x1		Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --					
Cycle 3	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --			Imaging
  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	If MRI of abdomen and/or pelvis is desired, please place order. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
		  	NM BONE SCAN WHOLE BODY	Interval: --	Occurrences: --	Comments:	Whole body bone scan: Tc- 99m Bone Scintigraphy. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --					
Cycle 4	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --					
Cycle 5	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --			Imaging
  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	If MRI of abdomen and/or pelvis is desired, please place order. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
		  	NM BONE SCAN WHOLE BODY	Interval: --	Occurrences: --	Comments:	Whole body bone scan: Tc- 99m Bone Scintigraphy. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --				Day 15	Perform every 1 day x1		Nursing Orders
  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
					
Cycle 6	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --					
Cycle 7	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --			Imaging
  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	If MRI of abdomen and/or pelvis is desired, please place order. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
		  	NM BONE SCAN WHOLE BODY	Interval: --	Occurrences: --	Comments:	Whole body bone scan: Tc- 99m Bone Scintigraphy. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --					
Cycle 8	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --				Day 15	Perform every 1 day x1		Nursing Orders
  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
					
Cycle 9	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --					
Cycle 10	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --			Imaging
  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	If MRI of abdomen and/or pelvis is desired, please place order. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
		  	NM BONE SCAN WHOLE BODY	Interval: --	Occurrences: --	Comments:	Whole body bone scan: Tc- 99m Bone Scintigraphy. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
					
Cycle 11	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --				Day 15	Perform every 1 day x1		Nursing Orders
  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
					
Cycle 12	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --					
Cycle 13	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --			Imaging
  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	If MRI of abdomen and/or pelvis is desired, please place order. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
		  	NM BONE SCAN WHOLE BODY	Interval: --	Occurrences: --	Comments:	Whole body bone scan: Tc- 99m Bone Scintigraphy. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
					
Cycle 14	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --				Day 15	Perform every 1 day x1		Nursing Orders
  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
					
Cycle 15	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --					
Cycle 16	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --			Imaging
  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	If MRI of abdomen and/or pelvis is desired, please place order. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
		  	NM BONE SCAN WHOLE BODY	Interval: --	Occurrences: --	Comments:	Whole body bone scan: Tc- 99m Bone Scintigraphy. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
					
Cycle 17	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --				Day 15	Perform every 1 day x1		Nursing Orders
  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
					
Cycle 18	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --					
Cycle 19	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --			Imaging
  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	If MRI of abdomen and/or pelvis is desired, please place order. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
		  	NM BONE SCAN WHOLE BODY	Interval: --	Occurrences: --	Comments:	Whole body bone scan: Tc- 99m Bone Scintigraphy. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
					
Cycle 20	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --				Day 15	Perform every 1 day x1		Nursing Orders
  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
					
Cycle 21	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --					
Cycle 22	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --			Imaging
  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	If MRI of abdomen and/or pelvis is desired, please place order. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
		  	NM BONE SCAN WHOLE BODY	Interval: --	Occurrences: --	Comments:	Whole body bone scan: Tc- 99m Bone Scintigraphy. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
					
Cycle 23	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --				Day 15	Perform every 1 day x1		Nursing Orders
  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 22	Interval: --	Occurrences: --	Comments:	PRO-CTCAE and FACT-GP5
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
					
Cycle 24	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Provider Communication
  	ONC PROVIDER COMMUNICATION 3	Interval: --	Occurrences: --	Comments:	Please issue paper prescription for these study medications:
PF-06821497 	875 mg PO BID. Administer with food. Swallow whole; do not chew. 
Enzalutamide 160 mg PO QD. Administer with or without food. Swallow whole; do not manipulate or chew.
			Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --					
EOT	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 34	Interval: --	Occurrences: --	Comments:	Study intervention accountability
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
		  	ECG 12-LEAD	Interval: --	Occurrences: --	Comments:	ECG assessments should precede blood collection for clinical laboratory tests.
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --			Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --		  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --			Imaging
  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	If MRI of abdomen and/or pelvis is desired, please place order. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
		  	NM BONE SCAN WHOLE BODY	Interval: --	Occurrences: --	Comments:	Whole body bone scan: Tc- 99m Bone Scintigraphy. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
					
28-day Safety Follow-up	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1		Nursing Orders
  	ONC NURSING COMMUNICATION 9	Interval: --	Occurrences: --	Comments:	Physical Exam
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Measure blood pressure, heart rate, temperature (celsius)
		  	MEASURE WEIGHT	Interval: --	Occurrences: --	Comments:	Measure weight (kg)
		  	ONC NURSING COMMUNICATION 10	Interval: --	Occurrences: --	Comments:	ECOG Performance Status
		  	ONC NURSING COMMUNICATION 11	Interval: --	Occurrences: --	Comments:	Contraception check
		  	ONC NURSING COMMUNICATION 14	Interval: --	Occurrences: --	Comments:	Prior/concomitant treatment(s)
		  	ONC NURSING COMMUNICATION 15	Interval: --	Occurrences: --	Comments:	Serious/nonserious AE monitoring: Report serious and non-serious adverse event information from time informed consent form is signed through screen failure or through a minimum of 28 days after the last dose of study intervention.
		  	ONC NURSING COMMUNICATION 16	Interval: --	Occurrences: --	Comments:	Symptomatic Skeletal Events
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 30	Interval: --	Occurrences: --	Comments:	Study intervention dispensation (PF-06821497 and/or enzalutamide)
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	Healthcare Resource Use for Hospitalizations
		  	ECG 12-LEAD	Interval: --	Occurrences: --	Comments:	ECG assessments should precede blood collection for clinical laboratory tests.
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	ABSOLUTE NEUTROPHIL COUNT	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	CYSTATIN C WITH EGFR	Interval: --	Occurrences: --	Comments:	If Clinically Indicated.
Post-baseline, Cystatin C is measured if and only if serum creatinine increase post-baseline is observed.
		  	CD 4 SUBSET	Interval: --	Occurrences: --	Comments:	CD4 count to be obtained if lymphocyte count is <500 microliter
		  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --					
LTFU	Repeat 1 time	Cycle length: 1 day	Day 1	Perform every 1 day x1		Nursing Orders
  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Survival Status
		  	ONC NURSING COMMUNICATION 20	Interval: --	Occurrences: --	Comments:	BPI-SF, FACT-P, EQ-5D-5L
		  	ONC NURSING COMMUNICATION 32	Interval: --	Occurrences: --	Comments:	Collection of new Antineoplastic/Investigational Therapy (may be completed via phone)
		  	ONC NURSING COMMUNICATION 33	Interval: --	Occurrences: --	Comments:	Diagnosis of Second Primary Malignancy
			Labs
  	PSA, TOTAL AND FREE	Interval: --	Occurrences: --			Imaging
  	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	If MRI of abdomen and/or pelvis is desired, please place order. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.
		  	NM BONE SCAN WHOLE BODY	Interval: --	Occurrences: --	Comments:	Whole body bone scan: Tc- 99m Bone Scintigraphy. 
Tumor assessments are to be performed during the EOT visit if the reason was other than central radiographically confirmed disease progression and it has been >= 8 weeks since the last assessment. Not required during follow up if disease progression has been confirmed by BICR.